nach oben

Erschienen in:

01.08.2013 | Original Article

Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study

verfasst von: R. P. Jones, P. Sutton, R. M. D. Greensmith, A. Santoyo-Castelazo, D. F. Carr, R. Jenkins, C. Rowe, J. Hamlett, B. K. Park, M. Terlizzo, E. O’Grady, P. Ghaneh, S. W. Fenwick, H. Z. Malik, G. J. Poston, N. R. Kitteringham

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The response of colorectal liver metastases to the cytotoxic agent irinotecan varies widely. Attempts to correlate tumour metabolism with response have been mixed. This study investigated the hepatic metabolism of irinotecan as a potential predictor of tumour response to irinotecan-eluting beads (DEBIRI).

Methods

Ten patients with colorectal liver metastases were treated with 200 mg irinotecan (as DEBIRI) as part of the PARAGON II study. Hepatic expression of key metabolising enzymes was measured using mass spectrometry-based proteomics. Serum drug concentrations and hepatic irinotecan metabolism were characterised and correlated with tumour response.

Results

Serum concentrations of irinotecan metabolites did not correlate with hepatic metabolism or pathological response. There was a strong correlation between hepatic CES-2 expression and activation of irinotecan (r ² = 0.96, p < 0.001). Patients with a UGT1A1*28 6/7 SNP showed no difference in drug metabolism or pathological response. Hepatic CES-2 mediated activation of irinotecan clearly correlated with tumour replacement by fibrosis (r ² = 0.54, p = 0.01).

Conclusion

This study provides the first evidence that hepatic activation of irinotecan predicts tumour response. Delivery of liver-targeted irinotecan to normal liver tissue rather than tumour may be a more rational approach to maximise response.

Morris EJA, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L et al (2010) Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97(7):1110–1118PubMedCrossRef

Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135PubMedCrossRef

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766PubMedCrossRef

Folprecht G, Grothey A, Alberts S, Raab H-R, Köhne C-H (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8):1311–1319PubMedCrossRef

Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18(2):299–304PubMedCrossRef

Poultsides GA, Bao F, Servais EL, Hernandez-Boussard T, Dematteo RP, Allen PJ et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19(9):2797–2804PubMedCrossRef

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016PubMedCrossRef

Nordlinger B (2012) EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol 30, abstr 3508

Vauthey J-N, Pawlik TM, Ribero D, Wu T–T, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072PubMedCrossRef

10.

Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E et al (1999) CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 80(3–4):364–370PubMedCrossRef

11.

Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260(27):14873–14878PubMed

12.

Xu G, Zhang W, Ma MK, McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8(8):2605PubMed

13.

Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA (2011) The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 57(1):86–93PubMedCrossRef

14.

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T et al (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2(1):43–47PubMedCrossRef

15.

Mathijssen RHJ, de Jong FA, van Schaik RHN, Lepper ER, Friberg LE, Rietveld T et al (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96(21):1585–1592PubMedCrossRef

16.

Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582):143–152PubMedCrossRef

17.

Koopman M, Knijn N, Richman S, Seymour M, Quirke P, van Tinteren H et al (2009) 6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer Suppl 7(2):321–322CrossRef

18.

Jones RP (2012) Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): a multi-institute phase II study in resectable metastases. J Clin Oncol 30, abstr 3613

19.

Wyatt J, Hübscher S, and Goldin R (2012) Standards and datasets for reporting cancer; liver resection specimens, 2nd edn. Royal College of Pathologists, London

20.

21.

Rowe C, Goldring CEP, Kitteringham NR, Jenkins RE, Lane BS, Sanderson C et al (2010) Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. J Proteome Res 9(5):2658–2668PubMedCrossRef

22.

Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11(3):298–300, 302

23.

Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR et al (1989) Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32(3):715–720PubMedCrossRef

24.

Fda US (2001) Guidance for industry: bioanalytical method validation. CDER, Rockville, MD

25.

Martin RCG, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M et al (2010) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198PubMedCrossRef

26.

Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395PubMed

27.

Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26(33):5344–5351PubMedCrossRef

28.

Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F et al (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26(16):2690–2698PubMedCrossRef

29.

Yu J, Shannon WD, Watson MA, McLeod HL (2005) Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 11(5):2053–2062PubMedCrossRef

30.

Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52(7):1103–1111PubMedCrossRef

31.

Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7(8):2182–2194PubMed

32.

Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL (2007) Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30(1):7–14PubMedCrossRef

33.

Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M et al (2008) Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 99(8):1239–1245PubMedCrossRef

34.

Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, Vogl TJ (2012) First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol 41(4):1213–1220PubMed

35.

de Jonge MJ, Verweij J, de Bruijn P, Brouwer E, Mathijssen RH, van Alphen RJ et al (2000) Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 18(1):195–203PubMed

36.

Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing ABM, Eisenacher M et al (2008) Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res 7(11):4678–4688PubMedCrossRef

37.

Yang J, Cai L, Huang H, Liu B, Wu Q (2012) Genetic variations and haplotype diversity of the UGT1 gene cluster in the Chinese population. PLoS One 7(4):e33988PubMedCrossRef

38.

Holmes RS, Wright MW, Laulederkind SJF, Cox LA, Hosokawa M, Imai T et al (2010) Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21(9–10):427–441PubMedCrossRef

39.

Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S et al (2005) Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 11(19 Pt 1):6901–6907PubMedCrossRef

40.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596PubMedCrossRef

41.

d’Esposito F, Nebot N, Edwards RJ, Murray M (2010) Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease. Br J Clin Pharmacol 70(3):400–408PubMedCrossRef

42.

Zhang Y, Cheng X, Aleksunes L, Klaassen CD (2012) Transcription factor-mediated regulation of carboxylesterase enzymes in livers of mice. Drug Metab Dispos 40(6):1191–1197PubMedCrossRef

43.

Leonardo CC, Doré S (2011) Dietary flavonoids are neuroprotective through Nrf2-coordinated induction of endogenous cytoprotective proteins. Nutr Neurosci 14(5):226–236PubMedCrossRef

44.

Barter ZE, Chowdry JE, Harlow JR et al (2008) Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 36(12):2405–2409PubMedCrossRef

Titel: Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study
verfasst von: R. P. Jones
P. Sutton
R. M. D. Greensmith
A. Santoyo-Castelazo
D. F. Carr
R. Jenkins
C. Rowe
J. Hamlett
B. K. Park
M. Terlizzo
E. O’Grady
P. Ghaneh
S. W. Fenwick
H. Z. Malik
G. J. Poston
N. R. Kitteringham
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2199-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study